Central nervous system lymphoma, including primary and secondary central nervous system lymphoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients aged 18–90 years, regardless of sex; 2.A confirmed diagnosis of central nervous system lymphoma, including primary or secondary central nervous system lymphoma, based on histopathology, cerebrospinal fluid cytology, or flow cytometry; 3.Availability of analyzable multiparametric brain MRI data, including the principal sequences of T1-weighted imaging, T2-weighted imaging, FLAIR, diffusion-weighted imaging, and contrast-enhanced T1-weighted imaging; 4.Availability of relevant clinical, pathological, laboratory, treatment, and follow-up data; 5.For patients included in the ctDNA analysis, availability of eligible plasma and/or cerebrospinal fluid ctDNA data;
Exclusion criteria
Exclusion criteria: 1.Poor-quality MRI images, substantial motion artifacts, or absence of essential MRI sequences that preclude lesion assessment or imaging-feature extraction; 2.Substantial missing clinical, pathological, treatment, or follow-up information that prevents determination of the main study outcomes; 3.Coexisting primary malignant tumors of the central nervous system that may interfere with imaging assessment or outcome determination; 4.Contraindications to MRI that prevent prospectively enrolled participants from completing the required imaging examinations; 5.Refusal to participate, withdrawal of informed consent, or inability to complete follow-up during the prospective study; 6.Other conditions considered unsuitable for inclusion by the investigators;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment response of central nervous system lymphoma; | — |
Countries
China
Contacts
Tongji Hospital of Tongji University